These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38028175)

  • 21. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review.
    Sheu NW; Jiang HJ; Wu CW; Chiang FY; Chiou HC; Hsiao PJ
    World J Surg Oncol; 2019 May; 17(1):84. PubMed ID: 31103041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma.
    Suoh M; Hagihara A; Yamamura M; Maruyama H; Taira K; Enomoto M; Tamori A; Fujiwara Y; Kawada N
    Intern Med; 2021 Feb; 60(4):545-552. PubMed ID: 33028766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review: anal and rectal changes after radiotherapy for prostate cancer.
    Krol R; Smeenk RJ; van Lin EN; Yeoh EE; Hopman WP
    Int J Colorectal Dis; 2014 Mar; 29(3):273-83. PubMed ID: 24150230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anorectal disorders.
    Janicke DM; Pundt MR
    Emerg Med Clin North Am; 1996 Nov; 14(4):757-88. PubMed ID: 8921768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The curative management of synchronous rectal and prostate cancer.
    Lavan NA; Kavanagh DO; Martin J; Small C; Joyce MR; Faul CM; Kelly PJ; O'Riordain M; Gillham CM; Armstrong JG; Salib O; McNamara DA; McVey G; O'Neill BD
    Br J Radiol; 2016; 89(1057):20150292. PubMed ID: 26539631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma.
    Suoh M; Fujii H; Nagata Y; Kotani K; Hagihara A; Enomoto M; Tamori A; Inaba M; Kawada N
    Clin J Gastroenterol; 2020 Oct; 13(5):860-866. PubMed ID: 32128670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma].
    Yang XR; Sun HC; Xie Q; Zhang WG; Jia WD; Zhao M; Zhao HT; Liu XF; Zhou LD; Yan S; Xu L; Wang NY; Ding Y; Zhu XD; Zhou J; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2023 Oct; 31(10):1018-1029. PubMed ID: 38016765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
    Cabanillas ME; Takahashi S
    Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A huge rectal ulcer due to argon plasma coagulation in a patient with radiation proctitis.
    Viso Vidal D; Jiménez Palacios M; Jorquera Plaza F
    Rev Esp Enferm Dig; 2020 Aug; 112(8):661-662. PubMed ID: 32686433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is the Pathologic Response of T3 Rectal Cancer to High-Dose-Rate Endorectal Brachytherapy Comparable to External Beam Radiotherapy?
    Garfinkle R; Lachance S; Vuong T; Mikhail A; Pelsser V; Gologan A; Morin NA; Vasilevsky CA; Boutros M
    Dis Colon Rectum; 2019 Mar; 62(3):294-301. PubMed ID: 30741768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results.
    Mahal BA; Ziehr DR; Hyatt AS; Neubauer-Sugar EH; O'Farrell DA; O'Leary MP; Steele GS; Niedermayr TR; Beard CJ; Martin NE; Orio PF; D'Amico AV; Devlin PM; Nguyen PL
    Brachytherapy; 2014; 13(5):442-9. PubMed ID: 24880584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Case of Tracheoesophageal Fistula in a Non-metastatic Site During Lenvatinib Treatment for Hepatocellular Carcinoma.
    Yokota K; Kitagawa H; Okamoto K; Namikawa T; Maeda H; Kobayashi M; Seo S
    Cancer Diagn Progn; 2023; 3(4):475-478. PubMed ID: 37405210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma.
    Yamauchi M; Ono A; Amioka K; Fujii Y; Nakahara H; Teraoka Y; Uchikawa S; Fujino H; Nakahara T; Murakami E; Okamoto W; Miki D; Kawaoka T; Tsuge M; Imamura M; Hayes CN; Ohishi W; Kishi T; Kimura M; Suzuki N; Arihiro K; Aikata H; Chayama K; Oka S
    Commun Med (Lond); 2023 Oct; 3(1):152. PubMed ID: 37880538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib.
    Nakashima S; Sekine A; Sawa N; Kawamura Y; Kono K; Kinowaki K; Kawada M; Hasegawa E; Akuta N; Suzuki Y; Ohashi K; Takaichi K; Ubara Y; Hoshino J
    Intern Med; 2022 Oct; 61(20):3083-3088. PubMed ID: 35342129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy.
    Cheng JC; Peng LC; Chen YH; Huang DY; Wu JK; Jian JJ
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1010-8. PubMed ID: 14575832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients.
    Prada PJ; Fernández J; Martinez AA; de la Rúa A; Gonzalez JM; Fernandez JM; Juan G
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):95-102. PubMed ID: 17707267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A biodegradable rectal balloon implant to protect the rectum during prostate cancer radiotherapy for a patient with active Crohn's disease.
    Vanneste BGL; Van Limbergen EJ; van de Beek K; van Lin E; Lutgens L; Lambin P
    Tech Innov Patient Support Radiat Oncol; 2018 Jun; 6():1-4. PubMed ID: 32095571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5 years: a case report.
    Imai T; Kobayashi H; Senaha T; Imaizumi T; Murata Y
    Surg Case Rep; 2022 Jan; 8(1):21. PubMed ID: 35084585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.